

Rec'd PCT/PTO

18 DEC 2005

#4

10/526 854

Express Mail Label No.:

Date of Deposit:

Attorney Docket No. 29326-028 NATL

**COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below my name.

I believe I am an original, first and sole inventor of the subject matter which is claimed and for which a utility patent is sought on the invention entitled:

**FIBRIN CELL SUPPORTS AND METHODS OF USE THEREOF**


that was filed on September 5, 2003 as a PCT application designating the United States, and was assigned PCT/IB2003/004506. A United States national phase application was filed on March 4, 2005 and given U.S.S.N. 10/526,854.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application designating at least one country other than the United States listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Appln. Number	Country (if PCT, so indicate)	Filing Date (dd/mm/yy)	Priority Claimed	
			Yes	No
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>



10/13/05

I hereby claim the benefit under Title 35, United States Code, § 119(e) or §120 of any United States application(s), or §365(c) of any PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:


Application No. (U.S.S.N.)	Filing Date (mm/dd/yy)	Status (Patented, Pending, Abandoned)
60/408,566	06 September 2002	
60/433,715	16 December 2002	

PCT International Applications designating the United States:

PCT International Application No.	PCT Filing Date	Status
PCT/IB2003/004506	05 September 2003	


I hereby appoint the attorneys and/or agents associated with Mintz Levin Cohn Ferris Glovsky & Popeo, Customer Number 30623 to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please address all telephone calls to Ivor R. Elrifi, Esq. at telephone number 617/542-6000.  
Please address all correspondence to Customer Number 30623.



VR  
10/13/05

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or patent issued thereon.

1-00  
  
Inventor's Signature: Vincent Ronfard

Full Name of Inventor: Vincent Ronfard

Citizenship: France


Residence: 67 Cherry Place, Newton, MA 02465-1505

Post Office Address: Same

10/13/05  
Date

MA

TRA 2066876v1

STATEMENT UNDER 37 CFR 3.73(B)Applicant/Patent Inventor Vincent RonfardApplication No./Patent No. 10/526,854Filed/Issue Date: March 4, 2005Entitled: FIBRIN CELL SUPPORTS AND METHODS OF USE THEREOFDFB Pharmaceuticals, Inc., a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership,  
university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.  
The extent (by percentage) of its ownership interest is \_\_\_\_\_ %

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:


1. From: Episource SA To: DFB Pharmaceuticals  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ Copies of assignments or other documents in the chain of title are attached.  
[NOTE: A separate copy (*Le.*, a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.081]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

 GINA SHISHIMA 45,104

Signature

November 15, 2005

Date

for Mark B. Wilson, Reg. No. 37,259

Printed or Typed Name

(512) 474-5201

Telephone Number

Attorney

Title

DFBP:011USC1

File Code

Express Mail Label No.: EV475167504US  
Date of Deposit: February 16, 2005

Attorney Docket No.: 17811-999

## ASSIGNMENT

**EpiSource SA**, a corporation organized under the laws of **Switzerland**, having principal offices at 1 Rue de Sébeillon, 1004 Lausanne, **Switzerland** ("the ASSIGNOR"), the undersigned, for good and valuable consideration, the receipt of which is hereby acknowledged, hereby assigns, sells and transfers to **DFB Pharmaceuticals, Inc.**, a corporation organized under the laws of **Texas**, having principal offices at 3909 Hulen Street, Fort Worth, Texas 76107, and its successors, assigns and legal representatives, all hereinafter referred to as the ASSIGNEE:

(1) the entire right, title and interest for the United States and in all countries, in and to any and all inventions, discoveries and applications which are disclosed in the patents and applications for patents as listed in Schedule A, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in the name of EpiSource SA at the ASSIGNEE, or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patents which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

EpiSource SA hereby authorizes and requests the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by EpiSource SA had this assignment, sale and transfer not been made.

EpiSource SA agrees, at any time, upon the request of the ASSIGNEE, to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries, or applications and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.


EpiSource SA further agrees at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

EpiSource SA hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.


EpiSource SA further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

For EpiSource SA:

Date: December 15, 2004


  
Signature of: \_\_\_\_\_  
Title: Director  
EpiSource SA

IN WITNESS WHEREOF,

  
Signature of witness: \_\_\_\_\_

this 15<sup>th</sup> day of December 2004  
Date of signing

IN WITNESS WHEREOF,

  
Signature of witness: \_\_\_\_\_

this 15<sup>th</sup> day of DECEMBER, 2004  
Date of signing

**For DFB Pharmaceuticals, Inc.:**

Date:

Brook S. Shul  
Signature of:  
Title: Chief Scientific Officer  
DFB Pharmaceuticals, Inc.

IN WITNESS WHEREOF,

Nab Singh  
Signature of witness:


this 15<sup>th</sup> day of December 2004  
Date of signing

IN WITNESS WHEREOF,

[Signature]  
Signature of witness:

this 15<sup>th</sup> day of December 2004  
Date of signing





Attorney Docket No.: 17811-999

**SCHEDULE A**

1. 17811-014-004 (M-14 AU)  
Australian Patent Application No. 60098/00  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
2. 17811-014-008 (M-14 CA)  
Canadian Patent Application No. 2,379,949  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
3. 17811-014-019 (M-14 EP)  
European Patent Application No. 00946228.4  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
4. 17811-014-032 (M-14 JP)  
Japanese Patent Application No. 2001-511156  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
5. 17811-014-061 (M-14 WO)  
PCT Patent Application No. PCT/IB00/01076  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
6. 17811-014 (M-14)  
United States Patent No. 6,548,058  
Entitled: "Keratinocyte Culture and Uses Thereof"
7. 17811-014 CIP (M-14 CIP)  
United States Patent No. 6,730,513  
Entitled: "Keratinocyte Culture and Uses Thereof"

8. 17811-014 NATL (M-14 NATL)  
United States Patent Application No. 10/031,188  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
9. 17811-015 (M-15)  
United States Patent No. 5,968,546  
Entitled: "Keratinocyte Culture from Precursor Cells"
10. 17811-017 (M-17)  
United States Patent No. 6,673,603  
Entitled: "Cell Paste Comprising Keratinocytes and Fibroblasts"
11. 17811-017 CIP (M-17 CIP)  
United States Patent Application No. 10/324,257  
Entitled: "Methods and Compositions for Tissue Regeneration"
12. 17811-017-032 CIP (M-17 CIP JP)  
Japanese Patent Application No. 2003-157362  
Entitled: "Methods and Compositions for Tissue Regeneration"
13. 17811-017-061 CIP (M-17 CIP WO)  
PCT Patent Application No. PCT/US03/27888  
Entitled: "Methods and Compositions for Tissue Regeneration"
14. 17811-017-004 (M-17 AU)  
Australian Patent Application No. 2001286952  
Entitled: "Methods and Compositions for Tissue Regeneration"
15. 17811-017-008 (M-17 CA)  
Canadian Patent Application No. 2426107  
Entitled: "Methods and Compositions for Tissue Regeneration"

16. 17811-017-019 (M-17 EP)  
European Patent Application No. 01966441.6  
Entitled: "Methods and Compositions for Tissue Regeneration"
17. 17811-017-061 (M-17 WO)  
PCT Patent Application No. PCT/US01/27104  
Entitled: "Methods and Compositions for Tissue Regeneration"
18. 17811-028 (M-28)  
United States Patent Application No. 10/655,435  
Entitled: "Fibrin Cell Supports and Methods of Use Thereof"
19. 17811-028-061 (M-28 WO)  
PCT Patent Application No. PCT/IB03/04506  
Entitled: "Fibrin Cell Supports and Methods of Use Thereof"